Interbat Corporate News
Interbat fine-tunes its therapeutic focus with inherent knowledge of pharmaceutical market.

Interbat manufactures over 300 products, mainly in premium-quality generics, and plans to open a new R&D facility next year to support its development of new products and to continue attracting top talent.
In 2000, Interbat started exports to Africa and now sells antibiotics and more than 50 other products in 10 different markets, including East Timor and Hong Kong. It has also successfully registered some of its formulations in Singapore and the Philippines.

With its long-standing position in Indonesia’s pharmaceutical industry complemented by a strong grasp of regulatory affairs, Interbat has become a trusted partner to leading multinationals seeking to enter the domestic market. Interbat leads in the probiotics field through a cooperation deal with Swedish biotechnology company BioGaia. In the premium baby care segment, Interbat serves as the official distributor of skin care products from French company Mustela. Anticipating a rise in demand for aesthetic products from working women and the rising middle class in Indonesia, Interbat is also aiming to grow its product offerings in the beauty and aesthetic segment.

“Through partnerships, we help ensure that more Indonesians have access to better health care,” Sukamto says. “We’re open to co-marketing, co-producing, licensing and other import and export arrangements as we seek to diversify our portfolio and expand our global reach.”

Source : SCMP.Com Website